NEWS・COLUMN
We send the latest information from SMC Laboratories.
MOA demonstration #3 【GLP-1】｜Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-…
Custom Model Service and its case study “CAIA-Rheumatoid Arthritis Model”
In recent years, we have received many requests about our services, starting from the establishment of patholo…
MOA demonstration #2【diponectin】｜A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as M…
Announcement of webinar: THRβ agonist and preclinical pharmacology study using by STAM™ mice
Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST…
Drug efficacy evaluation study for fibrotic diseases involving multiple organs
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such a…
Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on …
【出展のお知らせ】 第60回日本肝臓学会総会
この度、弊社は2024年6月13日（木）～14日（金）、熊本城ホールにて開催されます「第60回 日本肝臓学会総会」に出展いたしますので、お知らせいたします。 弊社オリジナルのMASH (NASH)-肝がんモ…
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in …
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of …